Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ERK- and USP9X-coupled regulation of thymidine kinase 1 promotes both its enzyme activity-dependent and enzyme activity-independent functions for tumor growth

ABSTRACT: ERK- and USP9X-coupled regulation of thymidine kinase 1 promotes both its enzyme activity-dependent and enzyme activity-independent functions for tumor growth

ORGANISM(S): Homo Sapiens

SUBMITTER: Zhimin Lu

PROVIDER: PXD058602 | iProX | Thu Dec 05 00:00:00 GMT 2024

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

Multiscale profiling of enzyme activity in cancer

Project description:Multiscale profiling of enzyme activity in cancer

| PRJNA789579 | ENA

Control of osteoblast regeneration by a train of Erk activity waves

Project description:We report here a dataset regarding the transcriptome of Erk active osteoblasts in regenerating zebrafish scales. We recently discovered that the marker osx:Venus-hGeminin anti-correlates with Erk activity in those cells. Thus, by sorting (using FACS) cells based on both the expression of an osteoblast marker (osx::H2A-mCherry) and the levels of hGeminin, we could sort osteoblasts into separate Erk+ and Erk- populations and perform RNAsequence (in triplicates). We found that dusp and sprouty transcripts are elevated in osteoblasts with high Erk activity. Specifically, dusp2, dusp5 and spry4 transcripts are predominant in scales and consistently present at higher levels in the population enriched for Erk+ cells.

2020-09-23 | GSE147551 | GEO

Multiscale profiling of enzyme activity in cancer [Bulk-seq]

Project description:Multiscale profiling of enzyme activity in cancer [Bulk-seq]

| PRJNA789563 | ENA

Multiscale profiling of enzyme activity in cancer [scRNA-seq]

Project description:Multiscale profiling of enzyme activity in cancer [scRNA-seq]

| PRJNA789581 | ENA

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors

Project description:This SuperSeries is composed of the following subset Series: GSE37698: Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors (SNP array) GSE37699: Aberrant ERK signaling causes resistance to EGFR kinase inhibitors Refer to individual Series

2012-10-01 | E-GEOD-37700 | biostudies-arrayexpress

Small and large intestine differ in basal ERK pathway activity

Project description:Small and large intestine differ in basal ERK pathway activity

| PRJNA548339 | ENA

Massively parallel characterization of CYP2C9 variant enzyme activity and abundance

Project description:Massively parallel characterization of CYP2C9 variant enzyme activity and abundance

| PRJNA694476 | ENA

Nuclear actin tunes ERK activity to promote somatic cell reprogramming into pluripotency

Project description:Yamanaka reprogramming is a stochastic process resulting in only a small fraction of somatic cells successfully converting into iPSCs. The molecular and cellular basis underlying this stochasticity remains elusive. Here we demonstrate that this stochasticity can be eliminated when ERK activity is tuned within a narrow range. This tuning can be accomplished by one tenth the concentration of MEK inhibitor in the 2i media. In the absence of pharmacologic ERK inhibition, cells fine tune ERK by morphological changes, growing taller by allocating more actin into their nucleus. A minimal cell height of 10 m is required for pluripotency, a cell geometric feature underlying the “dome-shaped” colony morphology of naïve pluripotent stem cells. Nuclear actin tunes ERK activity by binding to and immobilizing TFII-I, a transcription factor that binds and mediates ERK’s nuclear activation. This work uncovers a mechanistic link for how cell morphology controls cell identity. Insights into these fundamentally coupled processes provide effective approaches to overcome the stochasticity in reprogramming into pluripotency.

2024-01-01 | GSE229191 | GEO

Small and large intestine differ in basal ERK pathway activity

Project description:In this experiment, we determined the differences in the transcriptomes of freshly isolated murine small intestine and colon derived crypts. The data shows that the mRNA profiles of the two tissues significantly differ in their ground state. Interestingly, we found that the expression levels of ERK pathway components as well as their positive and negative regulators significantly differ between small intestinal and colonic crypts. This observation indicates that the ERK pathway displays higher basal activity in the small intestine compared to the colon.

2021-06-30 | GSE132546 | GEO

Aberrant ERK signaling causes resistance to EGFR kinase inhibitors

Project description:The clinical efficacy of EGFR kinase inhibitors is limited by the development of drug resistance. The irreversible EGFR kinase inhibitor WZ4002 is effective against the most common mechanism of drug resistance mediated by the EGFR T790M mutation. Here we show that in multiple complementary models harboring EGFR T790M, resistance to WZ4002 develops through aberrant activation of ERK signaling caused by either an amplification of MAPK1 or by downregulation of negative regulators of ERK signaling. Inhibition of MEK or ERK restores sensitivity to WZ4002, and the combination of WZ4002 and a MEK inhibitor prevents the emergence of drug resistance. The WZ4002 resistant MAPK1 amplified cells also demonstrate an increase both in EGFR internalization and a decrease in sensitivity to cytotoxic chemotherapy compared to the parental counterparts. Our findings provide insights into mechanisms of drug resistance to EGFR kinase inhibitors and highlight rational combination therapies that should be evaluated in clinical trials. Our study identifies ERK signaling as a mediator of resistance to irreversible pyrimidine EGFR inhibitors in EGFR T790M-bearing cancers. We further provide a therapeutic strategy to both treat and prevent the emergence of this resistance mechanism. To generate drug-resistant NCI-H1975 cell lines, non-small cell lung cancer (NSCLC) cells were exposed to increasing concentrations of WZ4002 similar to previously described methods. Individual clones from WZ4002-resistant (WZR) cells were isolated and confirmed to be drug resistant. Clone #6, designated as WZR6, was used in this study. For expression analysis, samples were prepared in triplicate from parental NCI-H1975 and NCI-H1975 WZR6 cells.

2012-10-01 | E-GEOD-37699 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data